Micromet (MITI) Enters Agreement with Lonza AG to Develop Blinatumomab
More News related to MITI
- Micromet to Host Annual Research & Development Day on February 10, 2010
- Micromet to Present at the 12th Annual BIO CEO & Investor Conference
- Roth Capital Upgrades Micromet (MITI) to Buy
- Needham & Co Initiates Coverage on Micromet (MITI) with a Buy
- Micromet to Present at the 28th Annual J.P. Morgan Healthcare Conference
More News related to Corporate News
- S&P Announces Change to US Index: TSRA for FIF
- RealNetworks (RNWK) and MTV Networks (VIA-B) to Split Off Joint Venture Rhapsody
- Watts Water (WTS) Board Approves Restructuring Program; Shutting Down 3 Plants, Cutting 95 Jobs
- Transcept Pharmaceuticals (TSPT) Granted U.S. Patent Covering Intermezzo Formulation
- AAR (AIR) Predicts Impact of Mesa's Bankruptcy on Q3 Results
Micromet, Inc. (NASDAQ: MITI) today announced that it has entered into an agreement for the process development and manufacture of blinatumomab (MT103) with Lonza AG, a market leading custom manufacturer of antibodies and other biologics.
Under the terms of the agreement, Lonza will manufacture blinatumomab for clinical trials. In addition, Lonza will develop the commercial scale process and will supply blinatumomab for the market if so requested by Micromet.
Blinatumomab is a BiTE antibody for the treatment of various hematologic cancers.
Related Categories
Corporate NewsStocks Mentioned
+0.01Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
